Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0HNC stock hub

LON/0HNC has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0HNCis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

7.7B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0HNC

In the news

Latest news · LON/0HNC

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.3

P25 12.9P50 16.9P75 23.5

Trailing P/E37.7

P25 15.9P50 22.9P75 35.8

ROE4.5

P25 -54.2P50 2.1P75 13.7

ROIC7.4

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0HNC market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

217

Groups with data

Currency

USD

Showing 217 of 217 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	3,221
Employees Change	181%
Employees Change Percent	5.95
Enterprise value	$7.1B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US09061G1013
Last refreshed	2026-05-10
Market cap	$7.7B
Price	$54.05
Price currency	USD
Rev Per Employee	762,316.71x
Sector	Healthcare
Sic	2836
Symbol	lon/0HNC
Website	https://www.biomarin.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.65%
EV Earnings	34.85x
EV/EBIT	17.11x
EV/EBITDA	15.06x
EV/FCF	12.21x
EV/Sales	2.98x
FCF yield	7.58%
Forward P/E	9.29x
P/B ratio	1.63x
P/E ratio	37.68x
P/S ratio	3.12x
PE Ratio3 Y	60.93x
PE Ratio5 Y	150.55x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	17.42%
EBITDA Margin	19.47%
FCF margin	23.66%
Gross margin	51.16%
Gross Profit	$1.3B
Gross Profit Growth	0.97%
Gross Profit Growth Q	-9.76%
Gross Profit Growth3 Y	17.97%
Gross Profit Growth5 Y	19.64%
Net Income	$203.5M
Net Income Growth	-48.7%
Net Income Growth Q	-43.17%
Net Income Growth Years	0%
Net Income Growth3 Y	55.4%
Net Income Growth5 Y	-19.5%
Pretax Margin	11.89%
Profit Margin	8.29%
Profit Per Employee	$63,185
Profitable Years	4
ROA	4.49
Roa5y	2.28
ROCE	7.24
ROE	4.48
Roe5y	3.83
ROIC	7.43
Roic5y	3.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-8.69%
Cagr3y	-16.87%
Cagr5y	-7.31%
EPS Growth	-48.33
EPS Growth Q	-43.42
EPS Growth Years	0
EPS Growth3 Y	55.68
EPS Growth5 Y	-19.74
FCF Growth	22.89%
FCF Growth Q	26.71%
FCF Growth3 Y	192.02%
FCF Growth5 Y	46.21%
OCF Growth	24.85%
OCF Growth Q	26.52%
OCF Growth3 Y	81.01%
OCF Growth5 Y	32.5%
Revenue Growth	9.9x
Revenue Growth Q	2.83x
Revenue Growth Quarters	17x
Revenue Growth Years	13x
Revenue Growth3 Y	14.27x
Revenue Growth5 Y	11.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$6.5B
Cash	$1.7B
Current Assets	$3.4B
Current Liabilities	$581.8M
Debt	$1.1B
Debt EBITDA	$2.24
Debt Equity	$0.23
Debt FCF	$1.88
Equity	$4.7B
Interest Coverage	24.56
Liabilities	$1.8B
Long Term Assets	$3.1B
Long Term Liabilities	$1.2B
Net Cash	$592.8M
Net Cash By Market Cap	$7.73
Net Cash Growth	18.17%
Net Debt EBITDA	$-1.24
Net Debt Equity	$-0.13
Net Debt FCF	$-1.02
Tangible Book Value	$4.4B
Tangible Book Value Per Share	$22.77
WACC	4.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.81
Inventory Turnover	1.24
Net Working Capital	$1.2B
Quick ratio	3.94
Working Capital	$2.9B
Working Capital Turnover	$0.74

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-8.69%
200-day SMA	56.29
3Y total return	-42.55%
50-day SMA	56.23
50-day SMA vs 200-day SMA	50under200
5Y total return	-31.59%
All Time High	126.9
All Time High Change	-57.39%
All Time High Date	2020-07-22
All Time Low	50.12
All Time Low Change	7.85%
All Time Low Date	2025-12-19
ATR	1.7
Beta	0.23
Ch YTD	-8.99
High	54.89
High52	65.92
High52 Date	2026-02-23
High52ch	-18%
Low	53.64
Low52	50.12
Low52 Date	2025-12-19
Low52ch	7.85%
Ma50ch	-3.87%
Price vs 200-day SMA	-3.97%
RSI	47.37
RSI Monthly	39.66
RSI Weekly	44.44
Sharpe ratio	-0.35x
Sortino ratio	-0.39
Total Return	-0.86%
Tr YTD	-8.99
Tr1m	-3.74%
Tr1w	0.08%
Tr3m	-7.08%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$427.7M
Operating Income Growth	-21.1
Operating Income Growth Q	-38.52
Operating Income Growth3 Y	78.02
Operating margin	17.42

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	192,153,823%
Net Borrowing	623,486,900
Shares Insiders	0.49%
Shares Institutions	97.44%
Shares Qo Q	2.83%
Shares Yo Y	0.86%
Short Ratio	4.97

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$439.2M
Average Volume	801.45x
Bv Per Share	24.34
CAPEX	$-81.2M
Ch1m	-3.74
Ch1w	0.08
Ch1y	-8.69
Ch3m	-7.08
Ch3y	-42.55
Ch5y	-31.59
Ch6m	5.68
Change	0.47%
Change From Open	-1
Close	53.8
Days Gap	1.49
Depreciation Amortization	48,777,947.5
Dollar Volume	12,810.3
Earnings Date	2026-04-24
EBIT	$427.7M
EBITDA	$478.1M
EPS	$1.06
F Score	5
FCF	$580.9M
FCF EV Yield	8.19x
Financing CF	613,077,777
Fiscal Year End	December
Founded	1,996
Goodwill	143,914,713.3
Graham Number	32.71872
Graham Upside	-39.47
Income Tax	$88.5M
Investing CF	257,123,223
Is Primary Listing	0
Last Earnings Date	2026-02-23
Last Report Date	2026-03-31
Lynch Fair Value	$7.17
Lynch Upside	-86.73
Ma150	56.03
Ma150ch	-3.53%
Ma20	54.27
Ma20ch	-0.4%
Net CF	1,532,506,632
Open	54.6
P FCF Ratio	13.2
P OCF Ratio	11.58
Position In Range	32.97
Ppne	702,758,491.5
Price Date	2026-05-08
Price EBITDA	$16.04
Ptbv Ratio	1.74
Relative Volume	0.3x
Revenue	2,455,422,118x
SBC By Revenue	5.77x
Share Based Comp	141,742,505
Tax By Revenue	3.6x
Tax Rate	30.3%
Tr6m	5.68%
Volume	237
Z Score	3.94

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0HNC pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0HNC stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0HNC?

Insider, institutional, and short-interest positioning.

Institutional ownership

+97.4%

Share of float held by funds and institutions

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0HNC momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.4

Neutral momentum band

Price vs 200-day MA

-4.0%

50/200-day relationship not available

Beta (5Y)

0.23

Less volatile than the market

Sharpe ratio

-0.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0HNC

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0HNC stock rating?

lon/0HNC is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0HNC analysis?

The full report lives at /stocks/lon/0HNC/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0HNC?

The latest report frames lon/0HNC around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0HNC page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.